Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L4	398	T ADJ "1249"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L5	3	(T ADJ "1249") same Peg$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L6	7	(T ADJ "1249") same Glycol$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L7	0	(gp41 same HIV same Glycol$) same pegyl$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L8	17	gp41 same HIV same Glycol$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L9	5791	Pegyl$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L10	702	Pegyl$ SAME linker	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L11	990	Pegyl$ SAME Length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L12	63	(Pegyl$ SAME linker) and (Pegyl$ SAME Length)	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L13	2	(("5464933") or ("5656480")).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2005/12/02 15:35
L14	8940	Glycol same peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L15	1500	(Glycol same peptide) same conjugat$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L16	1500	(Glycol same peptide) and ((Glycol same peptide) same conjugat$)	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L17	29	glycol ADJ length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L18	1354	PEG same Spacer	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35

L19	183	(PEG same Spacer) same length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L20	23	Polyethylene same glycol same protein same spacer same length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L21	4	(Polyethylene same glycol same protein same spacer same length) same peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L22	73	Glycol same length same increase same half adj life	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L23	1	("4,261,973").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2005/12/02 15:35
L24	1	("6348568").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2005/12/02 15:36
L25	134460	Insulin SMAE PEG	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L26	555	Insulin SAME PEG	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L27	0	Insulin SAME PEG SAME conmjugated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L28	102	Insulin SAME PEG SAME conjugated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L29	2	HIV SAME PEG SAME conjugated SAME Peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L30	1	("6469136").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2005/12/02 15:36
L31	5769	Pegylation or Pegylated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L32	694	(Pegylation or Pegylated) same linker	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L33	2249	(Pegylation or Pegylated) same attach$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36

L34	182	(Pegylation or Pegylated) same attach	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L35	143	(Pegylation or Pegylated) same coupl$ same aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L36	79	PEG-aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L37	3	(T ADJ "1249") same Peg$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L38	398	T ADJ "1249"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L39	4045	t adj "20"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L40	991	T-20	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L41	6	T-20 same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L42	2	T-20 same peptide same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L43	1	("6469136").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2005/12/02 15:36
L44	2	(T adj "20") same peptide same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L45	4	gp41 same peptide same peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L46	75	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L47	400838	L46 same polyethylene glycol	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L48	13	L46 same polyethylene same glycol	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L49	1	("6348568").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2005/12/02 15:36

L50	1201	Peg same aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L51	52	Polyethylene adj glycol adj aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L52	1	("6469136").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2005/12/02 15:36
L53	1	("5,252,714").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2005/12/02 15:36
L54	75	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L55	0	PEG adj YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L56	0	Peg-YTSLIHSLIEESQNQQEKNEQEL LELDKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L57	1	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF same peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L58	13	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF same polyethylene	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
S1	279	T ADJ "1249"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/06 14:15
S2	2	(T ADJ "1249") same Peg$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/18 16:01
S3	5	(T ADJ "1249") same Glycol$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/18 16:17
S4	0	(gp41 same HIV same Glycol$) same pegyl$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/18 16:18
S5	11	gp41 same HIV same Glycol$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/18 16:18
S6	4052	Pegyl$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 10:42
S7	483	Pegyl$ SAME linker	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 10:43

S8	790	Pegyl$ SAME Length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 10:43
S9	35	(Pegyl$ SAME linker) and (Pegyl$ SAME Length)	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 10:53
S10	2	(("5464933") or ("5656480")).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2004/10/19 11:16
S11	6722	Glycol same peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:17
S12	1062	(Glycol same peptide) same conjugat$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:17
S13	1062	(Glycol same peptide) and ((Glycol same peptide) same conjugat$)	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:17
S14	25	glycol ADJ length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:38
S15	1101	PEG same Spacer	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:38
S16	147	(PEG same Spacer) same length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:39
S17	17	Polyethylene same glycol same protein same spacer same length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:42
S18	1	(Polyethylene same glycol same protein same spacer same length) same peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:46
S19	42	Glycol same length same increase same half adj life	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:52
S20	1	("4,261,973").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2004/10/19 11:54
S21	1	("6348568").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2004/10/19 14:52
S22	112421	Insulin SMAE PEG	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 14:52

S23	408	Insulin SAME PEG	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 14:52
S24	0	Insulin SAME PEG SAME conmjugated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 14:52
S25	83	Insulin SAME PEG SAME conjugated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 15:07
S26	2	HIV SAME PEG SAME conjugated SAME Peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 15:07
S27	1	("6469136").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2004/10/19 16:07
S28	4100	Pegylation or Pegylated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 10:54
S29	483	(Pegylation or Pegylated) same linker	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 10:54
S30	1575	(Pegylation or Pegylated) same attach$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 10:55
S31	134	(Pegylation or Pegylated) same attach	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 11:29
S32	104	(Pegylation or Pegylated) same coupl$ same aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 12:57
S33	54	PEG-aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 12:57
S34	2	(T ADJ "1249") same Peg$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 14:31
S35	293	T ADJ "1249"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 14:26
S36	3407	t adj "20"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 14:31
S37	780	T-20	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 14:31
S38	5	T-20 same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 15:07

S39	1	T-20 same peptide same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 15:38
S40	1	("6469136").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2004/12/02 15:34
S41	1	(T adj "20") same peptide same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 15:39
S42	4	gp41 same peptide same peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 15:39
S43	57	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 17:29
S44	362071	S43 same polyethylene glycol	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 17:30
S45	13	S43 same polyethylene same glycol	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 17:36
S46	1	("6348568").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2004/12/02 17:36
S47	902	Peg same aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/06 14:16
S49	45	Polyethylene adj glycol adj aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/06 15:08
S50	1	("6469136").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2004/12/06 16:07
S51	1	("5,252,714").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2004/12/06 16:07
S52	57	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/07 15:21
S53	0	PEG adj YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/07 15:21
S54	0	Peg-YTSLIHSLIEESQNQQEKNEQEL LELDKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/07 15:21
S55	1	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF same peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/07 15:24

S56	13	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF same polyethylene	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/07 15:24

L39 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **251562-00-2** REGISTRY
ED Entered STN: 22 Dec 1999
CN L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminyl-L-α-glutamyl-L-tryptophyl-L-α-glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-α-glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-asparaginyl-L-α-glutamyl-L-tyrosyl-L-α-glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L-α-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-α-glutamyl-L-tryptophyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: WO9959615 PAGE: 68 claimed protein
CN T 1249
CN Tifuvirtide
FS PROTEIN SEQUENCE
MF C235 H341 N57 O67
CI MAN
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, EMBASE, IMSRESEARCH, PHAR, PROUSDDR, TOXCENTER, USAN, USPAT2, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

44 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
44 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L40 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **159519-65-0** REGISTRY
ED Entered STN: 13 Dec 1994
CN L-Phenylalaninamide, N-acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L-α-glutamyl-L-α-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-asparaginyl-L-α-glutamyl-L-glutaminyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-leucyl-L-α-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

OTHER NAMES:
CN 1: PN: US20020146415 PAGE: 10 claimed protein
CN 1: PN: US20030044411 PAGE: 10 claimed protein
CN 1: PN: WO0155439 SEQID: 1 claimed protein
CN 1: PN: WO0224149 PAGE: 24 claimed protein
CN 414: PN: WO0164013 FIGURE: 24 claimed protein
CN 636: PN: WO0151673 FIGURE: 54 claimed protein
CN 6: PN: WO2004091542 SEQID: 7 claimed protein
CN DP 178
CN Enfuvirtide
CN Fuzeon
CN GP 41-127-162AA
CN Pentafuside
CN T 20
CN T 20 (peptide)
FS PROTEIN SEQUENCE
DR 262434-79-7
MF C204 H301 N51 O64
CI MAN
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CIN, DIOGENES, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

239 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
243 REFERENCES IN FILE CAPLUS (1907 TO DATE)

(PAG) Poly(alkylene glycol)

```
> d his ful

     (FILE 'HOME' ENTERED AT 15:03:48 ON 02 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 15:04:00 ON 02 DEC 2005
L1             STRUCTURE UPLOADED
L2           9 SEA SSS SAM L1
L3          72 SEA SSS FUL L1

     FILE 'HCAPLUS' ENTERED AT 15:05:18 ON 02 DEC 2005
L4          31 SEA PLU=ON  L3
L5           6 SEA PLU=ON  L4 AND (PEG OR (POLYETHYLENE (W) GLYCOL) OR (POLY
               (W) ETHYLENE (W) GLYCOL))
               D L5 1-6 IBIB HITSTR
               D QUE STA

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:10:37 ON 02 DEC 2005
L6          16 SEA PLU=ON  L3
L7           9 SEA PLU=ON  L6 NOT L5

     FILE 'CASREACT' ENTERED AT 15:10:57 ON 02 DEC 2005
L8           3 SEA PLU=ON  L3
L9           2 SEA PLU=ON  L8 NOT L5
               D L9 1-2 IBIB RX
               D L9 1-2 SBIB

     FILE 'CASREACT' ENTERED AT 15:13:10 ON 02 DEC 2005
               D L9 1-2 SBIB

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:13:39 ON 02 DEC 2005
               D L7 1-9 CBIB
               D L7 1-9 IBIB HITSTR


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   30 NOV 2005  HIGHEST RN 869059-01-8
     DICTIONARY FILE UPDATES:  30 NOV 2005  HIGHEST RN 869059-01-8

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.
```

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE HCAPLUS

FILE COVERS 1907 - 2 Dec 2005 VOL 143 ISS 24
FILE LAST UPDATED: 1 Dec 2005 (20051201/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Dec 2005 (20051201/PD)
FILE LAST UPDATED: 1 Dec 2005 (20051201/ED)
CA INDEXING IS CURRENT THROUGH 1 Dec 2005 (20051201/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Dec 2005 (20051201/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005

FILE USPAT2
FILE COVERS 2001 TO PUBLICATION DATE: 1 Dec 2005 (20051201/PD)
FILE LAST UPDATED: 1 Dec 2005 (20051201/ED)
CA INDEXING IS CURRENT THROUGH 1 Dec 2005 (20051201/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Dec 2005 (20051201/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005

FILE CASREACT

FILE CONTENT:1840 - 27 Nov 2005 VOL 143 ISS 22

New CAS Information Use Policies, enter HELP USAGETERMS for details.

****
*
* CASREACT now has more than 10 million reactions *
*
****

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTATSH1654

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4	OCT 03	MATHDI removed from STN
NEWS 5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 8	OCT 27	Free KWIC format extended in full-text databases
NEWS 9	OCT 27	DIOGENES content streamlined
NEWS 10	OCT 27	EPFULL enhanced with additional content
NEWS 11	NOV 14	CA/CAplus - Expanded coverage of German academic research
NEWS 12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:38:01 ON 02 DEC 2005

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:38:16 ON 02 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8
DICTIONARY FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10625103Claim2and 3.str

L1 STRUCTURE UPLOADED

=> dis
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 14:38:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 204147 TO ITERATE

100.0% PROCESSED 204147 ITERATIONS 391 ANSWERS
SEARCH TIME: 00.00.03

L2 391 SEA SSS FUL L1

=> file hcap uspatful
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.76	161.97

FILE 'HCAPLUS' ENTERED AT 14:39:42 ON 02 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'USPATFULL' ENTERED AT 14:39:42 ON 02 DEC 2005

=> l2
L3 243 L2

=> L3 and T20
L4 3 L3 AND T20

=> L3 and T1249
L5 4 L3 AND T1249

=> L4 and L5
L6 2 L4 AND L5

=> d l3 1-3 ibib abs hitstr

L3 ANSWER 1 OF 243 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:1050829 HCAPLUS
DOCUMENT NUMBER: 143:353334
TITLE: PSMA formulations and use thereof for prostate cancer therapy
INVENTOR(S): Schulke, Norbert; Maddon, Paul J.; Olson, William C.
PATENT ASSIGNEE(S): PSMA Development Company, LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 167 pp., Cont.-in-part of U.S. Ser. No. 695,667.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005215472	A1	20050929	US 2004-976352	20041027
WO 2003034903	A2	20030501	WO 2002-US33944	20021023
WO 2003034903	A3	20031030		
WO 2003034903	B1	20040513		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004033229	A1	20040219	US 2003-395894	20030321
US 2004161776	A1	20040819	US 2003-695667	20031027

PRIORITY APPLN. INFO.:

US 2001-335215P	P	20011023
US 2002-362747P	P	20020307
US 2002-412618P	P	20020920
WO 2002-US33944	A2	20021023
US 2003-395894	A2	20030321
US 2003-695667	A2	20031027

AB The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compns. and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compns. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.

IT **253119-91-4**, RC-552
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvants for multimeric PSMA; PSMA formulations and uses thereof)

RN 253119-91-4 HCAPLUS

CN D-Glucose, 2-deoxy-6-O-[2-deoxy-2-[[(3R)-1-oxo-3-[(1-oxooctadecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphono-β-D-glucopyranosyl]-2-[[(3R)-1-oxo-3-[(1-oxohexadecyl)oxy]tetradecyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L3 ANSWER 2 OF 243 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:690412 HCAPLUS
DOCUMENT NUMBER: 143:262416
TITLE: Tripeptide Mimetics Inhibit the 20 S Proteasome by Covalent Bonding to the Active Threonines
AUTHOR(S): Braun, Hannes A.; Umbreen, Sumaira; Groll, Michael; Kuckelkorn, Ulrike; Mlynarczuk, Izabela; Wigand, Moritz E.; Drung, Ilse; Kloetzel, Peter-Michael; Schmidt, Boris
CORPORATE SOURCE: Clemens Schoepf-Institute for Organic Chemistry and Biochemistry, Darmstadt University of Technology, Darmstadt, D-64287, Germany
SOURCE: Journal of Biological Chemistry (2005), 280(31), 28394-28401
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Proteasomes play an important role in protein turnover in living cells. The inhibition of proteasomes affects cell cycle processes and induces apoptosis. Thus, 20 S proteasomal inhibitors are potential tools for the modulation of neoplastic growth. Based on MG132, a potent but nonspecific 20 S proteasome inhibitor, the authors designed and synthesized 22 compds. and evaluated them for the inhibition of proteasomes. The majority of the synthesized compds. reduced the hydrolysis of LLVY-7-aminomethylcoumarin peptide substrate in cell lysates, some of them drastically. Several compds. displayed inhibitory effects when tested in vitro on isolated 20 S proteasomes, with lowest IC50 values of 58 nM (chymotrypsin-like activity), 53 nM (trypsin-like activity), and 100 nM (caspase-like activity). Compds. 16, 21, 22, and 28 affected the chymotrypsin-like activity of the β5 subunit exclusively, whereas compds. 7 and 8 inhibited the β2 trypsin-like active site selectively. Compds. 13 and 15 inhibited all three proteolytic activities. Compound 15 was shown to interact with the active site by x-ray crystallog. The potential of these novel inhibitors was assessed by cellular tolerance and biol. response. HeLa cells tolerated up to 1 μM concns. of all substances. Intracellular reduction of proteasomal activity and accumulation of polyubiquitinated proteins were observed for compds. 7, 13, 15, 22, 25, 26, 27, and 28 on HeLa cells. Four of these compds. (7, 15, 26, and 28) induced apoptosis in HeLa cells and thus are considered as promising leads for anti-tumor drug development.

IT **863924-62-3 863924-64-5**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(inhibitor; tripeptide mimetics inhibit 20S proteasome by covalent bonding to active site threonines in relation to apoptosis induction and anti-tumor drug development)

RN 863924-62-3 HCAPLUS
CN L-α-Asparagine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 863924-64-5 HCAPLUS
CN L-α-Asparagine, N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 243 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:537072 HCAPLUS
DOCUMENT NUMBER: 143:265082
TITLE: Effect of monophosphoryl lipid A on antibody response to diphtheria toxin and its subunits
AUTHOR(S): Caglar, Kayhan; Aybay, Cemalettin; Ataoglu, Haluk
CORPORATE SOURCE: Department of Microbiology and Clinical Microbiology, Faculty of Medicine, Gazi University, Ankara, 06500, Turk.
SOURCE: APMIS (2005), 113(4), 256-263
CODEN: APMSEL; ISSN: 0903-4641
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Monophosphoryl lipid A (MPL) was evaluated for its ability to enhance the antibody response to diphtheria toxin and its fragment A and fragment B subunits. BALB/c mice were immunized s.c. with 1 Lf of diphtheria toxoid in the presence of 25 μg of MPL on days 0 and 14. Two weeks after the second immunization, sera were obtained from the mice and analyzed for antibody response to diphtheria toxin and its subunits. A new ELISA method, developed in the authors' laboratory, was used to measure antibody levels against the toxin, fragment A, and fragment B. It was observed that MPL significantly enhanced antibody responses to diphtheria toxin and its subunits. However, there was no statistical difference between anti-A and anti-B responses. The results indicated that MPL seems to be a potential candidate as an adjuvant for future diphtheria vaccine formulation.

IT **143110-73-0**, Monophosphoryl lipid A
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(effect of monophosphoryl lipid A on antibody response to diphtheria toxin and its subunits)
RN 143110-73-0 HCAPLUS
CN D-Glucose, 2-deoxy-6-O-[2-deoxy-2-[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphono-β-D-glucopyranosyl]-2-[[(3R)-1-oxo-3-[(1-oxohexadecyl)oxy]tetradecyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:120874 HCAPLUS
DOCUMENT NUMBER: 140:187354
TITLE: Preparation of PEGylated **T20** polypeptide conjugates as antiviral agents
INVENTOR(S): Bailon, Pascal Sebastian; Won, Chee-Youb

PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013164	A1	20040212	WO 2003-EP7710	20030716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493534	AA	20040212	CA 2003-2493534	20030716
EP 1527088	A1	20050504	EP 2003-766190	20030716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012889	A	20050614	BR 2003-12889	20030716
US 2004049018	A1	20040311	US 2003-623873	20030721
NO 2005000066	A	20050422	NO 2005-66	20050106
PRIORITY APPLN. INFO.:			US 2002-398195P P	20020724
			WO 2003-EP7710 W	20030716

AB Pegylated **T20** polypeptide compds. are provided. Also provided are pharmaceutical compns. containing pegylated **T20** polypeptide compds., and processes of making and using such compds. and compns. Propionaldehyde-PEG was reacted with **T20** to obtain propionaldehyde-PEG-**T20** conjugate (I). The IC50 of I was 0.261 μg/mL.

IT **650634-82-5DP**, reaction with **T20** peptide
650634-82-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of PEGylated **T20** polypeptide conjugates as antiviral agents)

RN 650634-82-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 650634-82-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2004:64499 USPATFULL
TITLE: Pegylated **T20** polypeptide
INVENTOR(S): Bailon, Pascal Sebastian, Florham Park, NJ, UNITED STATES
Won, Chee-Youb, Livingston, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049018	A1	20040311
APPLICATION INFO.:	US 2003-623873	A1	20030721 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-398195P	20020724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
NUMBER OF CLAIMS: 95
EXEMPLARY CLAIM: 1
LINE COUNT: 947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pegylated **T20** polypeptide compounds are provided. Also provided are pharmaceutical compositions containing pegylated **T20** polypeptide compounds, and methods of making and using such compounds and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **650634-82-5DP**, reaction with T20 peptide **650634-82-5P**
(preparation of PEGylated T20 polypeptide conjugates as antiviral agents)
RN 650634-82-5 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 650634-82-5 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2004:25315 USPATFULL
TITLE: Polyethylene glycol aldehydes
INVENTOR(S): Won, Chee-Youb, Livingston, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004019157	A1	20040129

APPLICATION INFO.: US 2003-623978 A1 20030721 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-398196P	20020724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
NUMBER OF CLAIMS: 86
EXEMPLARY CLAIM: 1
LINE COUNT: 974
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polyethylene glycol aldehyde compounds are provided. Methods of making and using such compounds, as well as chemical intermediates are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **650634-80-3P 650634-82-5P 650634-83-6P 650634-84-7P**
(manufacture of aldehyde derivs. of polyethylene glycol)
RN 650634-80-3 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-[2-oxo-2-[(4-oxobutyl)amino]ethyl]-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— $(CH_2)_3$ — CHO

RN 650634-82-5 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 650634-83-6 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-[2-[(4,4-diethoxybutyl)amino]-2-oxoethyl]-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 650634-84-7 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-[2-oxo-2-[(3-oxopropyl)amino]ethyl]-ω-[2-oxo-2-[(3-oxopropyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



=> d his

(FILE 'HOME' ENTERED AT 14:38:01 ON 02 DEC 2005)

FILE 'REGISTRY' ENTERED AT 14:38:16 ON 02 DEC 2005
L1 STRUCTURE UPLOADED
L2 391 S L1 FULL

FILE 'HCAPLUS, USPATFULL' ENTERED AT 14:39:42 ON 02 DEC 2005
L3 243 L2
L4 3 L3 AND T20
L5 4 L3 AND T1249
L6 2 L4 AND L5

=> d l5 1-4 ibib abs hitstr

L5 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:120875 HCAPLUS
DOCUMENT NUMBER: 140:187355
TITLE: Preparation of PEGylated **T1249** polypeptide conjugates as antiviral agents
INVENTOR(S): Bailon, Pascal Sebastian; Won, Chee-Youb
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013165	A1	20040212	WO 2003-EP7711	20030716

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2492954	AA	20040212	CA 2003-2492954		20030716
EP 1546193	A1	20050629	EP 2003-766191		20030716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2004171542	A1	20040902	US 2003-625103		20030722
NO 2005000067	A	20050422	NO 2005-67		20050106
PRIORITY APPLN. INFO.:			US 2002-398190P	P	20020724
			US 2003-439213P	P	20030110
			WO 2003-EP7711	W	20030716

AB Pegylated **T1249** polypeptide compds. are provided. Also provided are pharmaceutical compns. containing pegylated **T1249** polypeptide compds., and processes of making. Further provided is the use of pharmaceutical composition comprising, in admixt. with a pharmaceutically acceptable excipient, a PEGylated **T1249** polypeptide conjugate, for the preparation of a medicament for the inhibition of HIV infection. Propionaldehyde-PEG was reacted with **T1249** to obtain propionaldehyde-PEG-**T1249** conjugate. Antiviral efficacy of the conjugate was shown in rats.

IT **650634-82-5DP**, reaction with **T1249** **650634-82-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of PEGylated **T1249** polypeptide conjugates as antiviral agents)

RN 650634-82-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 650634-82-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2004:221771 USPATFULL
TITLE: Pegylated **T1249** polypeptide
INVENTOR(S): Bailon, Pascal Sebastian, Florham Park, NJ, UNITED STATES
Won, Chee-Youb, Livingston, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171542	A1	20040902
APPLICATION INFO.:	US 2003-625103	A1	20030722 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-439213P	20030110 (60)
	US 2002-398190P	20020724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
NUMBER OF CLAIMS: 149
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1472
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pegylated **T1249** polypeptide compounds are provided. Also provided are pharmaceutical compositions containing pegylated **T1249** polypeptide compounds, and methods of making. Further provided are methods of inhibiting HIV infection using such compounds and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **650634-82-5DP**, reaction with T1249 **650634-82-5P**
(preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)
RN 650634-82-5 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 650634-82-5 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER:	2004:64499 USPATFULL
TITLE:	Pegylated T20 polypeptide
INVENTOR(S):	Bailon, Pascal Sebastian, Florham Park, NJ, UNITED STATES Won, Chee-Youb, Livingston, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049018	A1	20040311
APPLICATION INFO.:	US 2003-623873	A1	20030721 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-398195P	20020724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
NUMBER OF CLAIMS: 95
EXEMPLARY CLAIM: 1
LINE COUNT: 947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pegylated T20 polypeptide compounds are provided. Also provided are pharmaceutical compositions containing pegylated T20 polypeptide compounds, and methods of making and using such compounds and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **650634-82-5DP**, reaction with T20 peptide **650634-82-5P**
(preparation of PEGylated T20 polypeptide conjugates as antiviral agents)
RN 650634-82-5 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 650634-82-5 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2004:25315 USPATFULL
TITLE: Polyethylene glycol aldehydes
INVENTOR(S): Won, Chee-Youb, Livingston, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004019157	A1	20040129	
APPLICATION INFO.:	US 2003-623978	A1	20030721	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-398196P	20020724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
NUMBER OF CLAIMS: 86
EXEMPLARY CLAIM: 1
LINE COUNT: 974
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polyethylene glycol aldehyde compounds are provided. Methods of making and using such compounds, as well as chemical intermediates are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **650634-80-3P 650634-82-5P 650634-83-6P 650634-84-7P**
(manufacture of aldehyde derivs. of polyethylene glycol)

RN 650634-80-3 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α-[2-oxo-2-[(4-oxobutyl)amino]ethyl]-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 650634-82-5 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 650634-83-6 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α-[2-[(4,4-diethoxybutyl)amino]-2-oxoethyl]-ω-[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 650634-84-7 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α-[2-oxo-2-[(3-oxopropyl)amino]ethyl]-ω-[2-oxo-2-[(3-oxopropyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



```
=> d que stat
L1                STR
```



```
Structure attributes must be viewed using STN Express query preparation.
L2          391 SEA FILE=REGISTRY SSS FUL L1
L3          243 SEA L2
L4            3 SEA L3 AND T20
L5            4 SEA L3 AND T1249
L6            2 SEA L4 AND L5


=> d his full

     (FILE 'HOME' ENTERED AT 14:38:01 ON 02 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 14:38:16 ON 02 DEC 2005
L1                STRUCTURE UPLOADED
                  DIS
L2          391 SEA SSS FUL L1

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 14:39:42 ON 02 DEC 2005
L3          243 SEA ABB=ON  PLU=ON  L2
L4            3 SEA ABB=ON  PLU=ON  L3 AND T20
L5            4 SEA ABB=ON  PLU=ON  L3 AND T1249
L6            2 SEA ABB=ON  PLU=ON  L4 AND L5
                  D L3 1-3 IBIB ABS HITSTR
                  D L4 1-3 IBIB ABS HITSTR
                  D L5 1-4 IBIB ABS HITSTR
                  D QUE STAT


     FILE HOME
```

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8
DICTIONARY FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE HCAPLUS

FILE COVERS 1907 - 2 Dec 2005 VOL 143 ISS 24
FILE LAST UPDATED: 1 Dec 2005 (20051201/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Dec 2005 (20051201/PD)
FILE LAST UPDATED: 1 Dec 2005 (20051201/ED)
HIGHEST GRANTED PATENT NUMBER: US6971121
HIGHEST APPLICATION PUBLICATION NUMBER: US2005268363
CA INDEXING IS CURRENT THROUGH 1 Dec 2005 (20051201/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Dec 2005 (20051201/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

C:\Program Files\Stnexp\Queries\1062510





chain nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
1-2 2-3 3-4 4-5 5-6 5-7 7-8 8-9 9-10 9-11
exact/norm bonds :
2-3 3-4 5-6 5-7 7-8 9-10
exact bonds :
1-2 4-5 8-9 9-11

Match level :
1:CLASS2:CLASS3:CLASS4:CLASS5:CLASS6:CLASS7:CLASS8:CLASS9:CLASS
10:CLASS11:CLASS